FATE THERAPEUTICS INC (FATE) Spending and interest coverage
- R&D / revenue · 12 months: Value 1546.03%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1546.03% | Research and development expense / revenue. Period ending 2026-06-30. $100.35M ÷ $6.49M × 100 ≈ 1546.03% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 100.35M USD | Research and Development Expense |
| Revenue | 6.49M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -133.59M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $100.35M | $6.49M | (m) | $-133.59M | (m) | 1546.03% | (m) | (m) | (m) |
| 2026-03-31 | $103.40M | $6.32M | (m) | $-139.42M | (m) | 1637.05% | (m) | (m) | (m) |
| 2025-12-31 | $107.83M | $6.65M | (m) | $-147.70M | (m) | 1622.46% | (m) | (m) | (m) |
| 2025-09-30 | $116.01M | $7.14M | (m) | $-174.73M | (m) | 1625.51% | (m) | (m) | (m) |
| 2025-06-30 | $124.83M | $8.47M | (m) | $-192.37M | (m) | 1473.73% | (m) | (m) | (m) |
| 2025-03-31 | $132.00M | $13.34M | (m) | $-200.49M | (m) | 989.87% | (m) | (m) | (m) |
| 2024-12-31 | $135.00M | $13.63M | (m) | $-210.28M | (m) | 990.40% | (m) | (m) | (m) |
| 2024-09-30 | $133.21M | $13.45M | (m) | $-196.60M | (m) | 990.62% | (m) | (m) | (m) |
| 2024-06-30 | $132.83M | $12.32M | (m) | $-195.50M | (m) | 1078.45% | (m) | (m) | (m) |
| 2024-03-31 | $139.10M | $6.48M | (m) | $-212.99M | (m) | 2147.34% | (m) | (m) | (m) |
| 2023-12-31 | $172.60M | $63.53M | (m) | $-190.51M | (m) | 271.66% | (m) | (m) | (m) |
| 2023-09-30 | $227.97M | $106.21M | (m) | $-206.85M | (m) | 214.64% | (m) | (m) | (m) |
| 2023-06-30 | $273.51M | $119.25M | (m) | $-241.97M | (m) | 229.36% | (m) | (m) | (m) |
| 2023-03-31 | $313.94M | $136.87M | (m) | $-262.51M | (m) | 229.38% | (m) | (m) | (m) |
| 2022-12-31 | $320.45M | $96.30M | (m) | $-308.39M | (m) | 332.77% | (m) | (m) | (m) |
| 2022-09-30 | $302.78M | $69.01M | (m) | $-313.35M | (m) | 438.73% | (m) | (m) | (m) |
| 2022-06-30 | $276.09M | $68.26M | (m) | $-281.58M | (m) | 404.49% | (m) | (m) | (m) |
| 2022-03-31 | $242.81M | $63.12M | (m) | $-245.25M | (m) | 384.69% | (m) | (m) | (m) |
| 2021-12-31 | $215.52M | $55.85M | (m) | $-216.99M | $0.00 | 385.92% | (m) | (m) | Reported |
| 2021-09-30 | $184.99M | $54.67M | (m) | $-181.01M | (m) | 338.35% | (m) | (m) | (m) |
| 2021-06-30 | $162.55M | $48.01M | (m) | $-157.88M | (m) | 338.60% | (m) | (m) | (m) |
| 2021-03-31 | $141.20M | $40.06M | (m) | $-139.80M | (m) | 352.46% | (m) | (m) | (m) |
| 2020-12-31 | $125.62M | $31.43M | (m) | $-128.09M | (m) | 399.64% | (m) | (m) | (m) |
| 2020-09-30 | $111.85M | $18.34M | (m) | $-123.76M | (m) | 609.87% | (m) | (m) | (m) |
| 2020-06-30 | $104.36M | $13.21M | (m) | $-119.40M | (m) | 789.93% | (m) | (m) | (m) |
| 2020-03-31 | $99.32M | $10.56M | (m) | $-114.77M | (m) | 940.26% | (m) | (m) | (m) |
| 2019-12-31 | $87.77M | $10.68M | (m) | $-100.73M | $1.75M | 821.82% | (m) | -57.49× | Reported |
| 2019-09-30 | $76.66M | $9.54M | (m) | $-88.39M | $1.64M | 803.61% | (m) | -53.77× | Reported |
| 2019-06-30 | $67.09M | $8.14M | (m) | $-77.96M | $1.67M | 824.62% | (m) | -46.60× | Reported |
| 2019-03-31 | $62.28M | $6.35M | (m) | $-73.48M | $1.69M | 981.34% | (m) | -43.51× | Reported |
| 2018-12-31 | $56.02M | $4.74M | (m) | $-67.09M | $1.70M | 1181.94% | (m) | -39.56× | Reported |
| 2018-09-30 | $51.82M | (m) | (m) | $-62.59M | $1.68M | (m) | (m) | -37.30× | Reported |
| 2018-06-30 | $46.76M | (m) | (m) | $-56.24M | $1.63M | (m) | (m) | -34.57× | Reported |
| 2018-03-31 | $37.87M | (m) | (m) | $-46.21M | $1.41M | (m) | (m) | -32.68× | Reported |
| 2017-12-31 | $34.36M | $4.11M | (m) | $-42.13M | $1.27M | 836.78% | (m) | -33.22× | Reported |
| 2017-09-30 | $30.70M | (m) | (m) | $-37.53M | $1.19M | (m) | (m) | -31.68× | Reported |
| 2017-06-30 | $28.93M | (m) | (m) | $-35.58M | $1.19M | (m) | (m) | -29.85× | Reported |
| 2017-03-31 | $27.78M | (m) | (m) | $-34.02M | $1.42M | (m) | (m) | -24.04× | Reported |
| 2016-12-31 | $26.45M | $4.40M | (m) | $-31.96M | $1.64M | 600.91% | (m) | -19.53× | Reported |
| 2016-09-30 | $25.66M | (m) | (m) | $-31.22M | $1.84M | (m) | (m) | -16.92× | Reported |
| 2016-06-30 | $23.85M | (m) | (m) | $-29.16M | $2.02M | (m) | (m) | -14.42× | Reported |
| 2016-03-31 | $21.93M | (m) | (m) | $-28.37M | $2.15M | (m) | (m) | -13.20× | Reported |
| 2015-12-31 | $19.86M | $2.43M | $2.40M | $-27.78M | $2.22M | 816.99% | 98.72% | -12.51× | Reported |
| 2015-09-30 | $18.29M | (m) | $2.53M | $-26.81M | $1.97M | (m) | (m) | -13.58× | Reported |
| 2015-06-30 | $17.37M | (m) | $2.48M | $-26.47M | $1.60M | (m) | (m) | -16.55× | Reported |
| 2015-03-31 | $16.48M | (m) | $2.17M | $-25.29M | $1.06M | (m) | (m) | -23.77× | Reported |
| 2014-12-31 | $16.43M | (m) | $2.43M | $-24.90M | $549.00K | (m) | (m) | -45.36× | Reported |
| 2014-09-30 | $15.60M | (m) | $2.21M | $-23.86M | $636.00K | (m) | (m) | -37.52× | Reported |
| 2014-06-30 | $14.90M | (m) | $2.66M | $-23.03M | $679.00K | (m) | (m) | -33.91× | Reported |
| 2014-03-31 | $14.00M | (m) | $2.35M | $-21.26M | $739.00K | (m) | (m) | -28.76× | Reported |
| 2013-12-31 | $12.01M | $971.00K | $1.55M | $-17.68M | $796.00K | 1236.56% | 160.04% | -22.20× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $2.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $12.00M | $2.67M | $155.00K | $-13.56M | $487.00K | 449.40% | 5.81% | -27.84× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $9.86M | $1.17M | $172.00K | $-13.29M | $127.00K | 842.56% | 14.70% | -104.67× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |